CIK 0002012593 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880724208
- Phone
- 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,490,340
- in 8 filings, $4.5M under 10b5-1 plans
Net +$17,533,565. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −3,056 | $25.43 | $78K | 573,746 |
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,242 | $24.91 | $56K | 38,819 |
| 2025-11-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,841 | $25.44 | $72K | 35,978 |
| 2025-11-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −3,156 | $24.84 | $78K | 406,486 |
| 2025-11-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,344 | $25.39 | $136K | 401,142 |
| 2025-10-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −7,418 | $25.73 | $191K | 410,724 |
| 2025-10-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −1,082 | $26.16 | $28K | 409,642 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −4,647 | $25.72 | $120K | 580,765 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −1,186 | $26.14 | $31K | 579,579 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −4,328 | $25.75 | $111K | 41,816 |
| 2025-10-15 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −755 | $26.17 | $20K | 41,061 |
| 2025-09-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −39,435 | $26.30 | $1.0M | 586,812 |
| 2025-09-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −1,400 | $26.87 | $38K | 585,412 |
| 2025-09-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −34,885 | $26.30 | $918K | 46,844 |
| 2025-09-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −700 | $27.04 | $19K | 46,144 |
| 2025-09-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,098 | $23.88 | $122K | 421,544 |
| 2025-09-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −3,402 | $24.66 | $84K | 418,142 |
| 2025-09-12 | Huber Reid M Director | Purchase | +20,400 | $24.48 | $499K | 20,400 |
| 2025-09-12 | PAUL STEVEN M Director | Purchase | +28,284 | $24.50 | $693K | 28,284 |
| 2025-09-12 | PAUL STEVEN M Director | Purchase | +13,382 | $24.97 | $334K | 41,666 |
Page 6 of 10 · 186 trades